baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

SENSEI BIOTHER. DL -,0001/ US81728A1088 /

2024-05-02 8:05:06 AM	Chg. +0.220	Volume	Bid8:59:53 PM	Ask8:59:53 PM	High	Low
1.150EUR	+23.66%	0 Turnover: 0.000	-Bid Size: -	-Ask Size: -	1.150	1.150

GlobeNewswire 04-24 Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Stu...

GlobeNewswire 04-09 Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

GlobeNewswire 04-04 Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of...

GlobeNewswire 03-22 Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

GlobeNewswire 03-06 Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

GlobeNewswire 02-28 Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire 02-07 Sensei Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire 01-04 Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

GlobeNewswire 2023-11-07 Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire 2023-11-03 Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

GlobeNewswire 2023-11-01 Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

GlobeNewswire 2023-10-25 Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 202...

GlobeNewswire 2023-10-23 Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ...

GlobeNewswire 2023-09-27 Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-1...

GlobeNewswire 2023-09-21 Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Sa...

GlobeNewswire 2023-09-13 Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinet...

GlobeNewswire 2023-08-30 Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 2022-03-10 Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights

GlobeNewswire 2022-03-09 Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors

GlobeNewswire 2022-03-03 Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

GlobeNewswire 2022-02-11 Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit

GlobeNewswire 2022-01-06 Sensei Biotherapeutics Announces Executive Promotions

GlobeNewswire 2021-12-16 Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

GlobeNewswire 2021-12-13 Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

GlobeNewswire 2021-11-19 Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

SENSEI BIOTHER. DL -,0001/ US81728A1088 /

If you wish to receive reply to your feedback, please provide your email address.